ClinicalTrials.gg
RecruitingNCT07397338Updated Nov 4, 2026

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

A Phase 1/2 interventional study of Daraxonrasib and Elironrasib in Advanced Solid Tumors, Metastatic Solid Tumors and Non-small Cell Lung Cancer (NSCLC), sponsored by Revolution Medicines, Inc.. Recruiting at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Revolution Medicines, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Nov 4, 202611 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
370
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc. — 8 open to participants now, 9 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Revolution Medicines, Inc..

Planned enrollment
8th of 13
370 · median 430
Started
2026
with 2 others
Phase 1/2
5 of 13
4 open now
Registered
12th of 13
by date

Among the 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc., this one is the 8th largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 1/2, and was the 12th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc. are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

Read the detailed description

This is an open-label, multicenter, Phase 1/2 study of RAS(ON) inhibitors in combination with ivonescimab with or without other anti-cancer agents in adults with advanced or metastatic solid tumors with a RAS mutation to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity. The study consists of three arms: Arm A:daraxonrasib in combination with ivonescimab; Arm B: elironrasib in combination with ivonescimab; and Arm C: zoldonrasib in combination with ivonescimab. All arms consist of two parts: Part 1- dose exploration and Part 2- dose expansion. Part 1 dose exploration will explore the safety and tolerability of individual RAS(ON) inhibitors in combination with ivonescimab. Part 2 dose expansion will explore the safety, tolerability, and antitumor activity of the individual RAS(ON) inhibitors with ivonescimab +/- anti-cancer therapies.

03

Conditions studied

  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Non-small Cell Lung Cancer (NSCLC)
  • NSCLC
  • Colorectal Cancer (CRC)
  • CRC

Keywords

  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Non-small Cell Lung Cancer
  • NSCLC
  • Colorectal Cancer
  • CRC
  • RAS
  • NRAS
  • KRAS
  • HRAS
  • RAS Mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old and has provided .
  • (ECOG) performance status of 0 or 1.
  • confirmed, locally advanced or solid tumor with documented RAS mutation in KRAS, HRAS, or NRAS.
  • Received and progressed or been intolerant to prior standard therapy (Part 1 Dose Exploration).
  • Non-squamous NSCLC without a treatable driver mutation in other oncogenes that has not received prior systemic treatment (Arms A \& B for Part 2 Dose Expansion).
  • Solid tumor or CRC previously treated with no more than 2 for advanced disease and progressed or been intolerant to prior standard therapies (Arm C for Part 2 Dose Expansion).
  • per v1.1
  • Adequate organ function (bone marrow, liver, kidney, coagulation, endocrine).
  • Able to take oral medications.

Exclusion criteria

Exclusion Criteria:

  • Head and neck squamous cell carcinoma.
  • Any conditions that may affect the ability to take or absorb study drug.
  • Major surgery within 4 weeks prior to receiving study drug(s).
  • Patient is unable or unwilling to comply with protocol-required study visits or procedures.
  • Other inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
370 participants (estimated)

Study arms

  • Experimental
    Arm A: Daraxonrasib + Ivonescimab Combination

    Dose Exploration and Dose Expansion (+ Carboplatin/Cisplatin + Pemetrexed)

    Drug: Daraxonrasib · Drug: Ivonescimab · Drug: Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)

  • Experimental
    Arm B: Elironrasib + Ivonescimab Combination

    Dose Exploration and Dose Expansion. Dose Expansion will include two separate cohorts: Cohort B1 (+ daraxonrasib) and Cohort B2 (+ Carboplatin/Cisplatin + Pemetrexed).

    Drug: Elironrasib · Drug: Ivonescimab · Drug: Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) · Drug: Daraxonrasib (Cohort B1 only)

  • Experimental
    Arm C: Zoldonrasib + Ivonescimab Combination

    Dose Exploration and Dose Expansion. Dose Expansion will include two separate cohorts: Cohort C1 and Cohort C2 (+ Cetuximab).

    Drug: Zoldonrasib · Drug: Ivonescimab · Drug: cetuximab (Cohort C2 Only)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients with adverse events (AEs)

    Number of patients with AEs as assessed by CTCAE v5.

    Time frame: Up to approximately 4 years

  2. Changes in vital signs

    Number of patients with changes in vital signs.

    Time frame: Up to approximately 4 years

  3. Changes in clinical laboratory test values

    Number of patients with changes in clinical laboratory test values.

    Time frame: Up to approximately 4 years

  4. Dose Limiting Toxicities

    Number of patients with dose limiting toxicities

    Time frame: 28 days

Secondary outcomes

  1. Concentration of RAS(ON) inhibitors and ivonescimab

    Trough and peak blood concentrations of RAS(ON) inhibitors and ivonescimab over time as applicable.

    Time frame: Up to Cycle 6 Day 1 (each cycle is 21 days)

  2. Objective Response Rate (ORR)

    ORR per response evaluation criteria in solid tumors (RECIST) v1.1

    Time frame: Up to approximately 4 years

  3. Duration of Response (DOR)

    DOR per RECIST v1.1

    Time frame: Up to approximately 4 years

  4. Disease Control Rate (DCR)

    DCR per RECIST v1.1

    Time frame: Up to approximately 4 years

  5. Time to response (TTR)

    TTR per RECIST v1.1

    Time frame: Up to approximately 4 years

  6. Progression free survival (PFS)

    PFS per RECIST v1.1

    Time frame: Up to approximately 4 years

  7. Anti-drug Antibody (ADA) of ivonescimab

    Number and percentage of patients with anti-ivonescimab antibody

    Time frame: Up to approximately 4 years

07

Study locations

19 of 19 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for May 2029, 40 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 40 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 9, 2026
StartActual
Jan 30, 2026
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added, 1 site removed
Show 11 added (11 United States)
  • Honor Health Research Institute · Scottsdale, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, United States
  • University of Kentucky HealthCare (UK HealthCare) · Lexington, United States
  • Siteman Cancer Center · St Louis, United States
  • John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, United States
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - NYU POC · New York, United States
  • Icahn School of Medicine at Mount Sinai · New York, United States
  • University Hospitals Cleveland Medical Center · Cleveland, United States
  • The Jame Outpatient Care West Campus · Columbus, United States
  • OHSU Knight Cancer Institute · Portland, United States
  • UPMC Hillman Cancer Center · Pittsburgh, United States
Show 1 removed
  • MD Anderson Cancer Center · Houston, United States
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    11 sites added, 1 site removed
    Show 11 added (11 United States)
    • Honor Health Research Institute · Scottsdale, United States
    • UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, United States
    • University of Kentucky HealthCare (UK HealthCare) · Lexington, United States
    • Siteman Cancer Center · St Louis, United States
    • John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, United States
    • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - NYU POC · New York, United States
    • Icahn School of Medicine at Mount Sinai · New York, United States
    • University Hospitals Cleveland Medical Center · Cleveland, United States
    • The Jame Outpatient Care West Campus · Columbus, United States
    • OHSU Knight Cancer Institute · Portland, United States
    • UPMC Hillman Cancer Center · Pittsburgh, United States
    Show 1 removed
    • MD Anderson Cancer Center · Houston, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07397338
Collaborators
Summit Therapeutics
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Jan 30, 2026
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Revolution Medicines Study Director
Contact
medinfo@revmed.com
1-844-2-REVMED

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daraxonrasib

Start the discussion